accounts of 10,772 million baht or 12% of total accounts receivable, decreasing from 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. For default receivables in
10,470 million baht or 11% of total accounts receivable, comparing to that of 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. The delinquent account receivables
reduction in personal loan receivable by 517 million baht or 1% from end of last fiscal year. The main assets were attributed to the portfolio of net account receivables which shared 99% of total assets
No: AH 04052024 May 14th, 2024 Subject: Management Discussion & Analysis (MD&A) for the Financial Statements of the 1st Quarter of Fiscal Year 2024 Ended as of March 31, 2024 To: The President The
, fraudulent or dishonest act that results in widespread damage, either under Thai or foreign laws; (4) being a person subject to a suspicious ground of being arranged for the person with the characteristics
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
cost was 10.05 Million Baht or an increase of 7.18 Million Baht which is equivalent to an increase of 250.17 % from the previous year. For the period of six months of the fiscal year 2017, the Company's
August 15, 2017 Subject: MD&A for the financial statements of the 2nd quarter of fiscal year 2017 ended as of June 30, 2017 To: The President The Stock Exchange of Thailand Aapico Hitech Public Company